Knipp lab:Research: Difference between revisions
mNo edit summary |
mNo edit summary |
||
| Line 21: | Line 21: | ||
Challenges associated with the development of pediatric medicines will require more accurate and predictive models in order to reduce the risks of conducting trials in pediatric populations. | Challenges associated with the development of pediatric medicines will require more accurate and predictive models in order to reduce the risks of conducting trials in pediatric populations. | ||
<br /><div style="width: 720px"> | <br /><br /><div style="width: 720px"> | ||
<center> | <center> | ||
<html><DIV align=right> | <html><DIV align=right> | ||
Revision as of 07:18, 18 December 2012
|
Major research interests: Dr. Knipp's research interests include the molecular and functional characterization of oligopeptide transporters, where he has been focusing on the characterization of the human Peptide/Histidine Transporter 1 isoform in human intestinal and blood brain barrier cell lines.
He is interested in determining the the effect of xenobiotics, particularly delineating the roles of DEHP and Bisphenol A, on placental fatty acid homeostasis and fetal development. He has also been interested in investigating the effects of processing induced dosage form variation on clinical performance utilizing in vitro and in vivo (porcine) models. His recent work has focused on the utilization of the porcine model for testing the pharmacokinetics of novel pediatric formulations developed within his laboratory.
Towards this aim, Mr. Wyatt Roth, a senior graduate student in the group, has focused on the development of orally disintegrating films (ODF) and tablets (ODT) for the delivery of rifampicin to infants and toddlers through a collaborative research grant with colleagues at Purdue and the Indiana University School of Medicine. During these studies, prototype ODF and ODT formulations of rifampicin have been developed and characterized. The novel ODF and ODT formulations were administered to juvenile pigs along with a commercially available capsule formulation in a crossover study design. The results of the preliminary studies revealed that PK parameters of rifampicin in the juvenile pig were very similar to those observed in human pediatric patients. It is the group’s long term goal that the juvenile porcine model will be used to facilitate and expedite the development of pediatric dosage forms for the mitigation of other diseases and disorders.
Challenges associated with the development of pediatric medicines will require more accurate and predictive models in order to reduce the risks of conducting trials in pediatric populations. <html><DIV align=right> Hosted by <a href="http://www.openwetware.org"><img src="http://openwetware.org/images/0/01/80x15_openwetware.png" border=0/></a></DIV></html> |
